Biogen Idec Inc. (NASDAQ:BIIB) has completed at least eight deals since the start of 2006 that include significant upfront payments and milestones. Source: BCIQ: BioCentury Online Intelligence

Year

Company

Value

Deal details

2009

Acorda Therapeutics Inc. (NASDAQ:ACOR)

$110M up front; $400M milestones

Exclusive, worldwide rights outside the U.S. to Acorda's Fampridine-SR for multiple sclerosis